OncoSignal
Live from Open Targets Platform, fetched 2026-11-12 07:28 UTC. Every row links to its source record.

FBXO11 F-box protein 11

ENSG00000138081 · protein coding · Open Targets profile

Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as DTL/CDT2, BCL6, SNAI1 and PRDM1/BLIMP1 (PubMed:17098746, PubMed:22113614, PubMed:23478441, PubMed:23478445, PubMed:23892434, PubMed:24613396, PubMed:24968003, PubMed:25827072, PubMed:29059170). The SCF(FBXO11) complex mediates ubiquitination and degradation of BCL6, thereby playing a role in the germinal center B- cells terminal differentiation toward memory B-cells and plasma cells (PubMed:22113614). The SCF(FBXO11) complex also mediates ubiquitination and degradation of DTL, an important step for the regulation of TGF- beta signaling, cell migration and the timing of the cell-cycle progression and exit (PubMed:23478441, PubMed:23478445). The SCF(FBXO11) complex also catalyzes ubiquitination and degradation of GSK3B-phosphorylated SNAI1 (PubMed:25827072, PubMed:29059170). Binds to and neddylates phosphorylated p53/TP53, inhibiting its transcriptional activity (PubMed:17098746). Plays a role in the regulatiom of erythropoiesis but not myelopoiesis or megakaryopoiesis (PubMed:33156908). Mechanistically, activates erythroid genes by mediating the degradation of BAHD1, a heterochromatin-associated protein that recruits corepressors to H3K27me3 marks (PubMed:33156908). Participates in macrophage cell death and inflammation in response to bacterial toxins by regulating the expression of complement 5a receptor 1/C5AR1 and IL-1beta (PubMed:33156908). Acts as a critical regulator to determine the level of MHC-II by mediating the recognition of degron at the P/S/T domain of CIITA leading to its ubiquitination and subsequent degradation via the proteasome (PubMed:37279268). Participates in the antiviral repsonse by initiating the activation of TBK1-IRF3-IFN-I axis (PubMed:36897010). Mediates the 'Lys-63'-linked ubiquitination of TRAF3 to strengthen the interaction between TRAF3 and TBK1 (PubMed:36897010). {ECO:0000269|PubMed:17098746, ECO:0000269|PubMed:22113614, ECO:0000269|PubMed:23478441, ECO:0000269|PubMed:23478445, ECO:0000269|PubMed:23892434, ECO:0000269|PubMed:24613396, ECO:0000269|PubMed:24968003, ECO:0000269|PubMed:25827072, ECO:0000269|PubMed:29059170, ECO:0000269|PubMed:33156908, ECO:0000269|PubMed:36897010, ECO:0000269|PubMed:37279268}.

In 12 of 15 cancers, the evidence for FBXO11 comes mainly from inherited variants

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751Lynch syndromeLynch syndromeLynch syndrome: somatic 0.88Lynch syndrome: germline 0.97endometrial carcinomaendometrial carcinomaendometrial carcinoma: somatic 0.60endometrial carcinoma: germline 0.95colon carcinomacolon carcinomacolon carcinoma: somatic 0.30colon carcinoma: germline 0.89ovarian cancerovarian cancerovarian cancer: somatic 0.77ovarian cancer: germline 0.72hereditary neoplastic syndromehereditary neoplastic syndromehereditary neoplastic syndrome: germline 0.95hereditary nonpolyposis colon cancerhereditary nonpolyposis colon cancerhereditary nonpolyposis colon cancer: germline 0.94ovarian neoplasmovarian neoplasmovarian neoplasm: somatic 0.77ovarian neoplasm: germline 0.49mismatch repair cancer syndromemismatch repair cancer syndromemismatch repair cancer syndrome: germline 0.94hereditary nonpolyposis colorectal carc…hereditary nonpolyposis colorectal carcinomahereditary nonpolyposis colorectal carcinoma: germline 0.92breast carcinomabreast carcinomabreast carcinoma: somatic 0.46breast carcinoma: germline 0.79gastric cancergastric cancergastric cancer: germline 0.88Burkitt lymphomaBurkitt lymphomaBurkitt lymphoma: somatic 0.70hereditary breast ovarian cancer syndro…hereditary breast ovarian cancer syndromehereditary breast ovarian cancer syndrome: germline 0.88hereditary breast carcinomahereditary breast carcinomahereditary breast carcinoma: germline 0.87mismatch repair cancer syndrome 1mismatch repair cancer syndrome 1mismatch repair cancer syndrome 1: germline 0.87

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

PROTAC
Database Ubiquitination, Half-life Data

gnomAD loss of function constraint: o/e 0.11116000264883041 (upper bound 0.17674000561237335). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of FBXO11's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of FBXO11's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.